The Faculty of Health Sciences at Queen’s University will create a research collaborative that will serve as an interdisciplinary space for research, innovation and knowledge translation in the field of psychedelics.
The launch of the psychedelics research collaborative is enabled by the Dimensions Health Fund in support of the Study of Psychedelics, established by Dimensions Health Centres (“Dimensions”). The collaborative will serve as a space to connect expertise across campus and stakeholders and partners in the broader community.
The collaborative will take a multi-pronged approach to supporting research and innovation in psychedelic-focused therapies. In addition to bringing together collaborators from across the university, the collaborative will allow the faculty to build relationships with stakeholders and experts in the community. Anticipated benefits include:
-
Furthering existing research and broadening the scope of psychedelic-assisted therapies and the psychedelics sector
-
Building awareness of the healing potential of psychedelics, and supporting early entry into the scientific and regulatory landscape
-
Laying a foundation for the develop
-
Aiding the development of best practice standards to ensure the safety, quality, and effectiveness of therapies, helping to ensure the sector’s long-term growth and sustainability
The collaborative will be aligned with Faculty of Health Science’s commitment to supporting Black, Indigenous and People of Colour (BIPOC) learners, staff and faculty, and the Equity, Diversity and Inclusion (EDI) initiative, launched in fall 2020.
Photo: queensu.ca
“The study of psychedelics is an important and emerging area of research and policy in Canada,” said Jane Philpott. “As we look to the critical need for further research, education, and knowledge translation, researchers in Canada’s post-secondary institutions have an important role to play, and the Faculty of Health Sciences at Queen’s University has positioned itself at the forefront.”
“As a company that is deeply committed to improving general well-being, we are excited by the potential for transformational healing that psychedelics have been shown to provide,” said Chris Dawson, CEO of Dimensions Health Centres. “We are confident that the research and development at Queen’s will shape the psychedelics industry for years to come.”
About Queen’s University
Queen’s University has a long history of scholarship, discovery, and innovation that has shaped our collective knowledge and helped address some of the world’s most pressing concerns. Home to more than 25,000 students, the university offers a comprehensive research-intensive environment with prominent strengths in physics, cancer research, geoengineering, data analytics, surveillance studies, art conservation, and mental health research. Welcoming and supporting students from all countries and backgrounds to a vibrant, safe, and supportive community is an important part of the Queen’s experience. Diverse perspectives and a wealth of experience enrich our campus and our community. A core part of our mission is to engage our students, staff, and faculty in international learning and research, both at home and abroad.
Queen’s University is ranked first in Canada and fifth in the world in the 2021 Time Higher Education Impact Rankings. The rankings measured over 1,200 post-secondary institutions on their work to advance the United Nations’ Sustainable Development Goals (SDGs).
About Dimensions Health Centres
Integrating the latest developments in neuroscience and neurobiology to create a revolutionary approach to mental health and well-being, Dimensions Health Centres provides immersive, psychedelic and psychedelic-inspired nature retreats for education and transformational healing. Founded in Toronto in 2021, Dimensions is a founding partner of the Psychedelics Research Collaborative at Queen’s University. Retreat, reset, renew @dimensionshealing. For more information, please visit: dimensionshealing.com.
Read the original release here.